Ion Channel Modulators Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Ion Channel Modulators Market  is segmented By Type (Ion Channel Opener, Ion Channel Blocker) By Channel Type (Ligand Gated Ion Channels, Voltage-Gated Ion Channels) By System (Cardiovascular, Nervous System, Endocrine System, Gastro Intestinal System, Others) By Application (Therapeutic, Research) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

The Global ion channel modulators market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Cell membranes contain pore-forming proteins called ion channels, which control the movement of charged particles called ions across the membrane. Numerous physiological functions, including as hormone release, muscular contraction, and nerve communication, depend on this ion flow. Depending on the gating mechanism, these ion channels are classified into ligand-gated ion channels, voltage-sensitive ion channels etc.

Ion channel modulators are the compounds or substances that alter the activity of the ion channel. The actions can be elicited either by closing or opening the ion channel which is followed by the cascade of events inside the cell. Any deviation or disruption of this normal physiological function of the ion channel will lead to ailments in the body. The ion channel modulators are of clinical importance, as they bring pharmacological changes for the treatment of these illnesses. 

Market Scope

To know more insights – Download free sample

Market Dynamics: Drivers

Rising research and development activities related to ion channel modulators

Ion channels play a vital role in drug discovery and development. Being a major target for pharmacological agents, they serve as a pathway for the treatment of various diseases associated with cardiovascular, neurological, renal, gastrointestinal, and other bodily systems. With the advancements of technology, to identify novel targets for drug substances, ion channels have become a center of attraction. 

Technological advancements such as the development of automated patch clamp (APC), genetic targets discovery, structure-based drug designing, etc has brought out the importance of ion channels as drug targets. This has led to rise in research and development activities focusing on ion channels which is expected to drive the market growth in the forecast period.  Moreover, several companies have been developing drugs that specifically target ion channels which is expected to further boost the market growth.

For instance, on August 31, 2023, a research study published in Nature Chemical Biology, conducted by Weill Cornell Medicine and RMIT University in Australia have found that certain ion channels, referred to as BK channels, have specific holes on their sides that may be accessible to pharmacological molecules. This novel finding is expected to pave the way for the creation of medications that target the BK channel to treat a variety of illnesses.

RaQualia Pharma Inc. has been working on a new kind of gastric acid secretion inhibitor called Tegoprazen, an innovative Potassium-Competitive Acid Blocker (P-CAB). Proton pump inhibitors have been the primary therapeutic choice for a variety of gastrointestinal diseases, and the discovery of this novel medicine targeting a different ion channel is expected to open up new avenues in drug research. Except for the United States, where the drug is undergoing phase 3 clinical studies, and Japan, where it is undergoing phase 1 trials, the medication is currently available worldwide. 

On February 15, 2023, the biotechnology business Maxion Therapeutics revealed that it has secured funding of over $16 million to help with the creation of innovative biologics that target G-protein coupled receptors and ion channels. This program will allow for the investigation of ion channels through the use of a brand-new family of medications known as antibodies.

On 15 November, 2023, NMD Pharma A/S announced that it had received funding of $80  million in series B. With this funding, the company hopes to carry out phase 2 clinical studies for its unique chemical, NMD670, which targets Charcot-Marie-Tooth disease, myasthenia gravis, and spinal muscular atrophy. This medication works by blocking the unique calcium ion channel known as CIC-1. NMD Pharma also sought to investigate this new ion channel and broaden its range of inhibitor medications intended to treat different ailments. Moreover, rising 

Moreover, the rising prevalence of chronic conditions, a rising number of pipeline drugs targeting ion channels is expected to further boost the market growth.

Restraints

Factors such as the high cost associated with the drug discovery, and difficulties associated with the study of ion channels are expected to restrain the market growth.

Segment Analysis

The global ion channel modulators market is segmented based on type, channel type, system, application and region.

The ion channel blockers in the type segment accounted for approximately 41.2% of the global ion channel modulators market share

Ion channel blockers are the agents which block the activity of the ion channel, they antagonize the normal physiological activity that takes place when the ion channel is open. They modify cell physiology by inhibiting ion flow through intracellular and subcellular membranes and they are typically employed to treat noncommunicable disorders like hypertension, pain, several neurological conditions etc. 

For instance, according to WHO data published on 16 March 2023, there are approximately 1.28 billion patients worldwide suffering from hypertension. Drugs that antagonize calcium channels also known as calcium channel blockers are one of the most widely prescribed drugs to treat hypertension. 

An article published in National Center for Biotechnology Information stated that sodium and calcium channels blockers are therapeutically play a crucial role in hypertension, ishchemic stroke, depression, epilepsy, neurodegenerative conditions, biopolar disorders etc. 

Moreover, several advancements have been made in the treatment of pain, especially neuropathic and chronic pain. Ion channels have been playing a crucial role in understanding the pain mechanism, and the agent that block these ion channel are being considered to be therapeutically important.

For instance, on July 27, 2023, New York University has released data regarding its new development in chronic pain treatment. Researchers at the university have developed gene therapy that targets ion channels, especially sodium channels called NaV1.7 for the treatment of chronic pain. Scientists have developed a molecule that indirectly blocks this sodium channel and it has been tested in animal models. The scientists have also added that this ion channel plays a promising role in the treatment of chronic pain including chemotherapy-induced neurotherapy.

Geographical Analysis 

North America is expected to dominate the market with 43.2% share in the global ion channel modulators market

North America is expected to dominate the market because the region has the highest spending on research and development activities in the pharmaceutical industry. In addition, the per capita spending by Americans on the drugs is far higher as compared to other regions which results in greater profits and higher revenue generation by the U.S. manufacturers. Moreover, the region has a higher prevalence of cardiovascular conditions, neurological conditions etc in which the ion channel modulators play a crucial role.

For instance, in September 2022 according to the data published by the U.S. department of health and Human Services, prescription drug costs in the United States are more than 2.5 times higher than those in other comparable high-income countries, indicating that Americans spend more for prescription drugs than people in any other country in the world.

Competitive Landscape

The major players in the ion channel modulators market include Pfizer Inc., Novartis AG, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Azurity Pharmaceuticals, Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Cipla Inc., and Aspen Pharmacure Australia Pty Ltd among others. 

COVID-19 Impact Analysis

The global market for ion channel modulators was affected by the COVID-19 pandemic. It has greatly affected the supply chain of essential medical commodities including pharmaceuticals. The low-middle-income countries were the ones that were greatly affected by this supply chain disruption. Due to a lack of potential indigenous manufacturers, these low-middle-income countries completely rely on imports. Due to restricted movement, and decreased production, there has been a delay in the delivery of essential pharmaceuticals. 

For instance, on September 22, 2023, according to an article published in Springer Nature, a study conducted in Tanzania, currently a low-middle income country revealed that COVID-19 has affected the supply chain of medical products that resulted in shortage, increased prices, and delayed delivery. In Tanzania, 90% of the pharmacists have reported a shortage of several pharmaceuticals. 

Why Purchase the Report?

• To visualize the global ion channel modulators market segmentation based on type, channel type, system, application and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of ion channel modulators market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global ion channel modulators market report would provide approximately 70 tables, 65 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies